89Zr-bevacizumab PET Imaging as Predictive Biomarker for Everolimus Efficacy in Patients With Neuroendocrine Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2015
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours
- Focus Biomarker; Therapeutic Use
- 02 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 02 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2011 New trial record